Avanos Medical (AVNS) Common Equity (2013 - 2026)

Avanos Medical has disclosed Common Equity across 14 years of filings, most recently posting $782.1 million for Q1 2026.

• Common Equity for Q1 2026 came in at $782.1 million, down 6.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $782.1 million (down 6.83% YoY), and the FY2025 annual result was $778.2 million, down 53.64% from the prior year.
• Common Equity came in at $782.1 million for Q1 2026 at Avanos Medical, up from $778.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.7 billion in Q4 2024 to a low of -$315.8 million in Q1 2024.
• The 5-year median for Common Equity is $782.1 million (2026), against an average of $711.9 million.
• Across the five-year window, Common Equity plunged 365.1% in 2024 and soared 365.8% in 2025, its largest moves.
• Avanos Medical's Common Equity stood at $1.3 billion in 2022, then decreased by 4.25% to $1.2 billion in 2023, then jumped by 35.78% to $1.7 billion in 2024, then slumped by 53.64% to $778.2 million in 2025, then gained by 0.5% to $782.1 million in 2026.
• The last three Common Equity figures came in at $782.1 million (Q1 2026), $778.2 million (Q4 2025), and $778.0 million (Q3 2025), per Business Quant data.